Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.

www.ty-pharm.com

Home

	Welcome by CEO
	Introduction of Staff

Introduction of Staff

Chen Xue Kui

Deputy General Manager

Chen Xue Kui joined Tianyuan in 2004.

As deputy general manager he is responsible for QA, QC, foreign affairs, internationalization issues and WHO prequalification.
Prior to joining Tianyuan, Chen Xue Kui worked in Chengdu Institute of Biological Products, P.R.China, respectively Yunnan Yunhe Pharmaceutical Co., Ltd. (Director Quality management) for over 18 years, gaining broad professional and management experience.
Responsibilities during that time included research on interferon and diverse vaccines (Helicobacter Pylori~, rabies~, HCV nucleic acid~,HIV DNA~), development of quality control test methods for diverse vaccines and implementation of GMP.
He gained international experience during his research on HIV poly-epitope DNA vaccine in Statens Serum Institute, Danmark in 2001 and 2002.
He is a graduate of West China University of Medical Sciences (formerly Sichuan Medical College).


	Han Dong Xu Deputy General Manager Erik D'Hondt Principal Scientist	Han Dongxu joined Tianyuan in 2007. As director of marketing and sales department, he is responsible for marketing and sales affairs in China. Han Dongxu has worked eight years in CDC. Since 1990, he began to take up sales of biological products. He was the president and general manger of Beijing Ramen Biology and has a long history of marketing management, mainly for vaccines besides other biological products. Han Dongxu is a graduate of Medical College of Henan University. In 2004, he completed MBA at Asia International Open University (Macau). Erik D'Hondt, Belgian nationality, joined Tianyuan in 2007. As principal scientist he gives professional support and assistance on WHO prequalification, improvement of product quality, introduction of advanced technology and implementation of cooperation projects. He has 33 years broad and outstanding international experience in multinational Pharma and public Biotech companies. During his 27 years at GSK, he developed most of the viral vaccines that GSK has on the market today, including MMR, Varicella, Influenza, Rotavirus, Hepatitis A, HepA-HepB Combination, Typhoid, etc. He has also extensive experience in cell culture technology. He won company and international rewards, including the Prix Galien, which is considered the industry's equivalent of the Nobel Prize and recognizes the technical, scientific and clinical research skills necessary to develop innovative medicines. The prize is the highest accolade for pharmaceutical research and development. He joined Innogenetics, Belgium as Vice President Therapeutics for 3 years and was Head of Global Project Management and early vaccine development of Berna Biotech, Switzerland for 2 years. From 2005 onwards, he has been working as independent consultant for small and big biotech, vaccine companies worldwide on research and development, regulatory initiatives and contacts, strategy and portfolio extension and management. Erik D'Hondt also developed an effective relationship with WHO on pandemic Influenza. He is a graduate of the University of Leuven, Belgium.